Davamotecan pegadexamer
- Generic Name
- Davamotecan pegadexamer
Combining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in People With Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide Treatment
- Conditions
- Metastatic Castration Resistant Prostate CancerProstate Neoplasms
- Interventions
- First Posted Date
- 2018-05-22
- Last Posted Date
- 2022-07-12
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 4
- Registration Number
- NCT03531827
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Alternative Dosing for CRLX101(NLG207) Alone, With Avastin and With mFOLFOX6 in Advanced Solid Tumors
- First Posted Date
- 2016-01-07
- Last Posted Date
- 2020-05-28
- Lead Sponsor
- NewLink Genetics Corporation
- Target Recruit Count
- 41
- Registration Number
- NCT02648711
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸START Midwest/Cancer & Hematology Centers of Western Michigan, PC, Grand Rapids, Michigan, United States
🇺🇸South Texas Accelerated Research Therapeutics (START), LLC, San Antonio, Texas, United States
A Study of CRLX101(NLG207) in Combination With Weekly Paclitaxel in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
- First Posted Date
- 2015-03-17
- Last Posted Date
- 2020-05-28
- Lead Sponsor
- NewLink Genetics Corporation
- Target Recruit Count
- 30
- Registration Number
- NCT02389985
- Locations
- 🇺🇸
University of Virginia Health System, Charlottesville, Virginia, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸University of Oklahoma / Stephenson Cancer Center, Oklahoma City, Oklahoma, United States
CRLX101(NLG207) in Combination With Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) Versus Standard of Care (SOC)
- Conditions
- Metastatic Renal Cell Carcinoma
- Interventions
- First Posted Date
- 2014-07-11
- Last Posted Date
- 2020-05-28
- Lead Sponsor
- NewLink Genetics Corporation
- Target Recruit Count
- 115
- Registration Number
- NCT02187302
- Locations
- 🇺🇸
University of California San Diego, La Jolla, California, United States
🇺🇸Cedars Sinai Medical Center, Los Angeles, California, United States
🇺🇸Texas Oncology, Dallas, Dallas, Texas, United States
Neoadjuvant Chemoradiotherapy With CRLX-101 and Capecitabine for Rectal Cancer
- Conditions
- Rectal Cancer
- Interventions
- First Posted Date
- 2013-12-12
- Last Posted Date
- 2020-11-03
- Lead Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Target Recruit Count
- 32
- Registration Number
- NCT02010567
- Locations
- 🇺🇸
University of North Carolina, Chapel Hill, North Carolina, United States
🇺🇸Rocky Mountain Cancer Center, Denver, Colorado, United States
🇺🇸Indiana University Simon Cancer Center, Indianapolis, Indiana, United States
Topotecan Hydrochloride or Cyclodextrin-Based Polymer-Camptothecin CRLX101 in Treating Patients With Recurrent Small Cell Lung Cancer
- Conditions
- Extensive Stage Small Cell Lung CancerRecurrent Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2013-03-04
- Last Posted Date
- 2020-06-26
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 29
- Registration Number
- NCT01803269
- Locations
- 🇺🇸
Decatur Memorial Hospital, Decatur, Illinois, United States
🇺🇸North Shore University Health System, Evanston, Illinois, United States
🇺🇸University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
CRLX101 in Combination With Bevacizumab for Recurrent Ovarian/Tubal/Peritoneal Cancer
- Conditions
- Fallopian Tube CancerOvarian CancerPrimary Peritoneal Cancer
- Interventions
- First Posted Date
- 2012-07-27
- Last Posted Date
- 2018-07-02
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 63
- Registration Number
- NCT01652079
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Brigham and Women's Hospital, Boston, Massachusetts, United States
Pilot Trial of CRLX101 in Treatment of Patients With Advanced or Metastatic Stomach, Gastroesophageal, or Esophageal Cancer That Cannot be Removed by Surgery
- Conditions
- Adenocarcinoma of the EsophagusAdenocarcinoma of the Gastroesophageal JunctionDiffuse Adenocarcinoma of the StomachIntestinal Adenocarcinoma of the StomachMixed Adenocarcinoma of the StomachRecurrent Esophageal CancerRecurrent Gastric CancerSquamous Cell Carcinoma of the EsophagusStage IIIB Esophageal CancerStage IIIB Gastric Cancer
- Interventions
- Other: Laboratory biomarker analysisOther: Pharmacological studies
- First Posted Date
- 2012-06-06
- Last Posted Date
- 2018-02-01
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 10
- Registration Number
- NCT01612546
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
A Phase 2 Study of CRLX101(NLG207) in Patients With Advanced Non-Small Cell Lung Cancer
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Other: Best Supportive Care
- First Posted Date
- 2011-06-27
- Last Posted Date
- 2020-05-28
- Lead Sponsor
- NewLink Genetics Corporation
- Target Recruit Count
- 157
- Registration Number
- NCT01380769
- Locations
- 🇷🇺
State Healthcare Institution: Bryansk Regional Oncology Center, Bryansk, Russian Federation
🇷🇺Kursk Regional Oncology Center, Kursk, Russian Federation
🇷🇺Non-Government Medical Institution: Central Clinical Hospital #2, Moscow, Russian Federation
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.